Adjuvance Technologies Inc.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Adjuvance Technologies Inc. - overview

Established

2009

Location

Lincoln, NE, US

Primary Industry

Biotechnology

About

Adjuvance Technologies Inc. is a technology firm specializing in innovative solutions tailored to enhance operational efficiency across various sectors, including healthcare, finance, and technology. Founded in 2009 and headquartered in Lincoln, US, Adjuvance Technologies Inc. focuses on delivering advanced technological solutions.


The company has undergone strategic developments but there are no records of significant pivots or mergers. The founders, David Gin and Jeffrey Gardner, have contributed their expertise to the growth of the firm, which has secured a total of two deals. Their latest funding round was a Series A, raising USD 20. 00 mn on January 29, 2020, led by 5Y Capital, bringing the total amount raised to USD 20.


00 mn. Adjuvance Technologies Inc. offers innovative solutions designed to meet the needs of clients across sectors, particularly focusing on operational efficiency in technology, healthcare, and finance. Their flagship products utilize advanced algorithms and data analytics for informed decision-making.


Services cater to a diverse client base, including SMEs and large corporations, addressing challenges such as resource management and customer engagement. The company operates in key markets, including North America, Europe, and select regions in Asia, serving a global audience. The company generates revenue through a structured transaction model primarily featuring subscription-based services and direct partnerships with clients. Clients engage with Adjuvance on a contractual basis to access specific services, ensuring predictable revenue streams.


The pricing structures are tiered to accommodate various budgets, enhancing customer retention and establishing the company as a vital partner in clients' operational success. Adjuvance Technologies Inc. plans to leverage the recent Series A funding of USD 20. 00 mn to develop new products and expand into new markets.


The company aims to launch its upcoming product line by mid-2021, targeting expansion into emerging markets in Asia and Europe by the end of 2022. The funding will support product development and market entry initiatives, enhancing their operational capabilities and customer outreach.


Current Investors

5Y Capital, Nebraska Angels

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceuticals

Website

www.adjuvancetechnologies.com

Company Stage

Series A

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.